Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
Notice 5d2b1c5f6d094d72ad9916f20fc33ed3 · solicitation BAA-23-100-SOL-00004
Agency
ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE
Office
BARDA - ASPR / DAAPPO / BARDA DCMA
Offers due
Not stated
Reserved for
Open to anyone A set-aside is a contract reserved for one category of small business.
Stage
Award
Estimated value
$213,943,726 awarded
Industry codes
Not stated
Place of performance
Jersey City, NJ
Already awarded. Scynexis, Inc. won this on 25 September 2026, for $213,943,726.
Break this one down
Paste this notice number into BidShred and it downloads the attachments and returns every requirement with its page number.